AML
Selected indexed studies
- Emerging agents and regimens for AML. (J Hematol Oncol, 2021) [PMID:33757574]
- Biomarkers as targets for CAR-T/NK cell therapy in AML. (Biomark Res, 2023) [PMID:37330575]
- Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions. (Cancers (Basel), 2024) [PMID:39199685]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Emerging agents and regimens for AML. (2021) pubmed
- Biomarkers as targets for CAR-T/NK cell therapy in AML. (2023) pubmed
- Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions. (2024) pubmed
- Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. (2022) pubmed
- CPX-351 (vyxeos) in AML. (2020) pubmed
- AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances. (2020) pubmed
- The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. (2023) pubmed
- Recent advances in AML with mutated NPM1. (2024) pubmed
- CEBPA-Associated Familial Acute Myeloid Leukemia (AML). (1993) pubmed
- Targeted therapy in NPM1-mutated AML: Knowns and unknowns. (2022) pubmed